Allergy, Immunology and Rheumatology
Nephrology
Pharmacology and Therapeutics
.jpg "Jerome Lane, MD (he/him/his) photo")
Jerome Lane, MD (he/him/his)
Associate Professor of Pediatrics
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Ellen Cody, MD, MS
Assistant Professor
Washington University in St. Louis School of Medicine
Saint Louis, Missouri, United States
Session
Description: Brief Description of Overall Session: Discuss the advances in treatment of lupus nephritis specifically on T cell and B cell directed therapies for both induction and maintenance therapies. This session will provide updates on the cutting-edge research on lupus nephritis pathogenesis, recent clinical trials on biologic therapies, and future developments in treatment.
Topic/title: Do we really need cyclophosphamide?
Objective: Discuss the updates in lupus pathogenesis and the role of B cells. Provide an overview of non-cyclophosphamide containing regimens for induction and maintenance therapy. Discuss the indications for cyclophosphamide rather than MMF and Eurolupus vs NIH regimens.
Topic/title: Voclosporin and calcineurin inhibitors does it really improve outcomes in lupus nephritis?
Objective: Discuss the role of calcineurin inhibitors in the treatment of lupus nephritis. Discuss the difference between Voclosporin and other CNIs. Provide context for choosing CNIs for treatment compared to risk for nephrotoxicity.
Topic/title: Utility of Belimumab as a steroid sparing agent in lupus nephritis
Objective: Discuss the role of Belimumab in lupus treatment and effect on reducing long term steroid exposure in lupus nephritis. Review the role of BAFF in lupus pathogenesis and the potential of combination therapy of Belimumab with B cell depletion.
Topic/title: B cell depletion, moving beyond Rituximab
Objective: Discuss the effects of depletion of circulating and tissue B cells on lupus. Discuss recent clinical trials on B cell depleting agents such as Obinutuzumab, Rituximab/Obinutuzumab, and the potential for CAR T cell B cell depletion for lupus treatment. Discuss the risk for hypogammaglobulinemia after B cell depletion.
Speaker: Scott E. Wenderfer, M.D, PhD (he/him/his) – University of British Columbia Faculty of Medicine
Speaker: Ankana Daga, MD – Boston Children's Hospital
Speaker: Daryl Okamura, MD (he/him/his) – Seattle Children's
Speaker: Beatrice Goilav, MD (she/her/hers) – The Children's Hospital at Montefiore